Ex Vivo Immunotherapy for Hyperglycemia in Type 2 Diabetes Mellitus

NCT02169531 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

25

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes Mellitus
Hyperglycemia

Interventions

DRUG: ex vivo Activated Immune Cells

Sponsor

B & Y Technologies

Collaborators

[object Object]
[object Object]